Combinations of chemo-, immuno-, and gene therapies using nanocarriers as a multifunctional drug platform

Caroline Hopkins, Kaila Javius-Jones, Yixin Wang, Heejoo Hong, Quanyin Hu, Seungpyo Hong

Research output: Contribution to journalReview articlepeer-review

5 Citations (Scopus)

Abstract

Introduction: Cancer immunotherapies have created a new generation of therapeutics to employ the immune system to attack cancer cells. However, these therapies are typically based on biologics that are nonspecific and often exhibit poor tumor penetration and dose-limiting toxicities. Nanocarriers allow the opportunity to overcome these barriers as they have the capabilities to direct immunomodulating drugs to tumor sites via passive and active targeting, decreasing potential adverse effects from nonspecific targeting. In addition, nanocarriers can be multifunctionalized to deliver multiple cancer therapeutics in a single drug platform, offering synergistic potential from co-delivery approaches. Areas covered: This review focuses on the delivery of cancer therapeutics using emerging nanocarriers to achieve synergistic results via co-delivery of immune-modulating components (i.e. chemotherapeutics, monoclonal antibodies, and genes). Expert opinion: Nanocarrier-mediated delivery of combinatorial immunotherapy creates the opportunity to fine-tune drug release while achieving superior tumor targeting and tumor cell death, compared to free drug counterparts. As these nanoplatforms are constantly improved upon, combinatorial immunotherapy will afford the greatest benefit to treat an array of tumor types while inhibiting cancer evasion pathways.

Original languageEnglish
Pages (from-to)1337-1349
Number of pages13
JournalExpert Opinion on Drug Delivery
Volume19
Issue number10
DOIs
Publication statusPublished - 2022

Bibliographical note

Publisher Copyright:
© 2022 Informa UK Limited, trading as Taylor & Francis Group.

All Science Journal Classification (ASJC) codes

  • Pharmaceutical Science

Fingerprint

Dive into the research topics of 'Combinations of chemo-, immuno-, and gene therapies using nanocarriers as a multifunctional drug platform'. Together they form a unique fingerprint.

Cite this